204 related articles for article (PubMed ID: 33161237)
1. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.
Mimoto R; Kobayashi T; Imawari Y; Kamio M; Kato K; Nogi H; Toriumi Y; Hirooka S; Uchida K; Takeyama H
Breast Cancer Res Treat; 2014 Sep; 147(2):317-24. PubMed ID: 25156580
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
[TBL] [Abstract][Full Text] [Related]
4. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Steenbruggen TG; Schaapveld M; Horlings HM; Sanders J; Hogewoning SJ; Lips EH; Vrancken Peeters MT; Kok NF; Wiersma T; Esserman L; van 't Veer LJ; Linn SC; Siesling S; Sonke GS
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977227
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factors in oligometastatic breast cancer.
van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
Steenbruggen TG; Wolf DM; Thijssen B; Sanders J; Cornelissen S; Salgado R; Mittempergher L; Bhaskaran R; Broeks A; Lips EH; Siesling S; Sonke GS; Horlings HM; van 't Veer LJ
JCO Precis Oncol; 2023 Sep; 7():e2200670. PubMed ID: 37738542
[TBL] [Abstract][Full Text] [Related]
9. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution.
Lacaze JL; Chira C; Glemarec G; Monselet N; Cassou-Mounat T; De Maio E; Jouve E; Massabeau C; Brac de la Perrière C; Selmes G; Ung M; Nicolai V; Cabarrou B; Dalenc F
Breast Cancer Res Treat; 2023 Apr; 198(3):463-474. PubMed ID: 36790573
[TBL] [Abstract][Full Text] [Related]
11. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
Bamias A; Stenzl A; Brown SL; Albiges L; Babjuk M; Birtle A; Briganti A; Burger M; Choudhury A; Colecchia M; De Santis M; Fanti S; Fonteyne V; Gallucci M; Rivas JG; Huddart R; Junker K; Kroeze S; Loriot Y; Merseburger A; Montironi R; Necchi A; Oing C; Oldenburg J; Ost P; Pinkawa M; Ribal MJ; Rouprêt M; Thoeny H; Zilli T; Hoskin P
Eur Urol; 2023 Oct; 84(4):381-389. PubMed ID: 37217391
[TBL] [Abstract][Full Text] [Related]
12. Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study.
Xie Y; Ma J; Xia X; Zheng H; Gou Q
Cancer Control; 2022; 29():10732748221130568. PubMed ID: 36164749
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
14. Oligometastatic Breast Cancer: How to Manage It?
Barberi V; Pietragalla A; Franceschini G; Marazzi F; Paris I; Cognetti F; Masetti R; Scambia G; Fabi A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207648
[TBL] [Abstract][Full Text] [Related]
15. Defining Oligometastatic Bladder Cancer: A Systematic Review.
Bamias A; Stenzl A; Zagouri F; Andrikopoulou A; Hoskin P
Eur Urol Open Sci; 2023 Sep; 55():28-37. PubMed ID: 37662704
[TBL] [Abstract][Full Text] [Related]
16. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
17. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
18. SABR in oligometastatic breast cancer: Current status and future directions.
Stewart R; White M; Tan J; Siva S; Karroum L; David S
Breast; 2021 Dec; 60():223-229. PubMed ID: 34739890
[TBL] [Abstract][Full Text] [Related]
19. Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.
Merloni F; Palleschi M; Casadei C; Romeo A; Curcio A; Casadei R; Stella F; Ercolani G; Gianni C; Sirico M; Cima S; Sarti S; Cecconetto L; Di Menna G; De Giorgi U
Ther Adv Med Oncol; 2023; 15():17588359231161412. PubMed ID: 36950272
[TBL] [Abstract][Full Text] [Related]
20. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
